Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B Virus in vitro using conventional antiviral agents and supercoiled‐DNA active compounds

Primary duck hepatocyte (PDH) cultures, congenitally infected with the duck hepatitis B virus (DHBV), were grown on feeder cell layers of irradiated human embryonic lung fibroblasts and then exposed to a number of compounds with recognized or potential antiviral activity. These compounds included conventional antiviral agents, reverse transcriptase inhibitors, compounds with activity to supercoiled‐DNA, and DNA‐binding agents. Twenty‐three compounds were evaluated, and 13 were found to inhibit significantly viral DNA replication. Seven of these compounds (ellipticine, amsacrine, coumermycin A1, Adriamycin, mitozantrone, chloroquine, and neocarzinostatin) acted at the level of viral SC DNA and significantly inhibited production of duck hepatitis B surface antigen (DHBsAg). Conventional agents that inhibited DHBV DNA replication included ganciclovir, acyclovir, bromovinyldeoxyuridine, ribavirin, phosphonoformate, and dideoxyadenosine. Except for dideoxyadenosine, these inhibitors of viral DNA synthesis did not significantly inhibit DHBsAg production. Two additional compounds, novobiocin and nalidixic acid, altered the pattern of viral DNA replication, especially the generation and processing of viral SC DNA, and also inhibited the production of DHBsAg. Several compounds acting at the level of viral SC DNA have now been identified and may offer potential for the management of chronic hepatitis B virus infection.

[1]  T. Shikata,et al.  Effect of 3′‐azido‐3′‐deoxythymidine on replication of duck hepatitis B virus in vivo and in vitro , 1989, Journal of medical virology.

[2]  J. Zeldis,et al.  Preliminary evidence that azidothymidine does not affect hepatitis B virus replication in acquired immunodeficiency syndrome (AIDS) patients , 1989, Journal of medical virology.

[3]  S. Locarnini,et al.  INHIBITION OF HBV DNA REPLICATION BY GANCICLOVIR IN PATIENTS WITH AIDS , 1989, The Lancet.

[4]  C. Trépo,et al.  Prolonged duck hepatitis B virus replication in duck hepatocytes cocultivated with rat epithelial cells: A useful system for antiviral testing , 1989, Hepatology.

[5]  D. Tyrrell,et al.  In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus , 1989, Antimicrobial Agents and Chemotherapy.

[6]  O. Yokosuka,et al.  Expression of pre-S1, pre-S2, and C proteins in duck hepatitis B virus infection. , 1988, Virology.

[7]  M. Peters,et al.  Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. , 1988, Annals of internal medicine.

[8]  H. Blum,et al.  Duck hepatitis B virus: DNA polymerase and reverse transcriptase activities of replicative complexes isolated from liver and their inhibition in vitro. , 1988, Virology.

[9]  R. Epstein.  TOPOISOMERASES IN HUMAN DISEASE , 1988, The Lancet.

[10]  C. Trépo,et al.  Main properties of duck hepatitis B virus DNA polymerase: comparison with the human and woodchuck hepatitis B virus DNA polymerases. , 1987, Antiviral research.

[11]  Heather M. Smith,et al.  Loss of HBsAg with interferon‐α therapy in chronic hepatitis D virus infection , 1993, Journal of medical virology.

[12]  K. Shimokata,et al.  Effects of the epipodophyllotoxin VP-16-213 on herpes simplex virus type 2 replication. , 1987, The Journal of general virology.

[13]  O. Yokosuka,et al.  Effects of adenine arabinoside on serum and intrahepatic replicative forms of duck hepatitis B virus in chronic infection , 1987, Hepatology.

[14]  R. Snapka.  Topoisomerase inhibitors can selectively interfere with different stages of simian virus 40 DNA replication. , 1986, Molecular and cellular biology.

[15]  J. Summers,et al.  Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells , 1986, Cell.

[16]  M. Omata,et al.  Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks. , 1986, Gastroenterology.

[17]  T. Beerman,et al.  Measurement of bleomycin, neocarzinostatin, and auromomycin cleavage of cell-free and intracellular simian virus 40 DNA and chromatin. , 1986, Molecular pharmacology.

[18]  J. Summers,et al.  In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus , 1986, Journal of virology.

[19]  H. Thomas,et al.  Approaches to the Treatment of Hepatitis B Virus and Delta-Related Liver Disease , 1986, Seminars in liver disease.

[20]  A. Zuckerman,et al.  Taxonomic classification of human hepatitis B virus. , 1986, Intervirology.

[21]  O. Yokosuka,et al.  Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: Analysis of intrahepatic replicative hepatitis B virus DNA , 1985, Hepatology.

[22]  S. Schalm,et al.  ACYCLOVIR ENHANCES THE ANTIVIRAL EFFECT OF INTERFERON IN CHRONIC HEPATITIS B , 1985, The Lancet.

[23]  J. Hoofnagle,et al.  Treatment of chronic type B hepatitis with multiple ten‐day courses of adenine arabinoside monophosphate , 1985, Journal of medical virology.

[24]  R. Perrillo,et al.  Comparative efficacy of adenine arabinoside 5' monophosphate and prednisone withdrawal followed by adenine arabinoside 5' monophosphate in the treatment of chronic active hepatitis type B. , 1985, Gastroenterology.

[25]  H. Will,et al.  Transcripts and the putative RNA pregenome of duck hepatitis B virus: Implications for reverse transcription , 1985, Cell.

[26]  D. Smee,et al.  Activities of arabinosyladenine monophosphate and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against ground squirrel hepatitis virus in vivo as determined by reduction in serum virion-associated DNA polymerase , 1985, Antimicrobial Agents and Chemotherapy.

[27]  G. Palù,et al.  Coumermycin inhibition of murine retrovirus replication in cultured cells. , 1984, The Journal of antimicrobial chemotherapy.

[28]  C. Trépo,et al.  Comparison of properties of woodchuck hepatitis virus and human hepatitis B virus endogenous DNA polymerases , 1984, Antimicrobial Agents and Chemotherapy.

[29]  L. Liu,et al.  Cleavage of DNA by mammalian DNA topoisomerase II. , 1983, The Journal of biological chemistry.

[30]  J. Summers,et al.  Experimental transmission of duck hepatitis B virus. , 1983, Virology.

[31]  T. Watanabe,et al.  Inhibition of retrovirus RNA-dependent DNA polymerase by novobiocin and nalidixic acid. , 1983, The Journal of general virology.

[32]  Z. Varghese,et al.  Acyclovir in hepatitis B antigen-positive chronic liver disease: inhibition of viral replication and transient renal impairment with iv bolus administration. , 1983, The Journal of antimicrobial chemotherapy.

[33]  J. Summers,et al.  Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate , 1982, Cell.

[34]  I. Cobden,et al.  初期食道静脈りゅう治療におけるテルイプレシン(グリプレシン)とバソプレシンの比較試験 , 1982 .

[35]  Lu-Yu Hwang,et al.  HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.

[36]  K. Meyer zum Büschenfelde,et al.  Inhibition of hepatitis B virus deoxyribonucleic acid polymerase by the 5'-triphosphates of 9-beta-D-arabinofuranosyladenine and 1-beta-D-arabinofuranosylcytosine , 1981, Antimicrobial Agents and Chemotherapy.

[37]  H. Edenberg.  Novobiocin inhibition of simian virus 40 DNA replication , 1980, Nature.

[38]  S. Hirschman,et al.  Inhibition of hepatitis B DNA polymerase by intercalating agents , 1978, Nature.

[39]  A. P. Norman,et al.  Letter: Skin wrinkling in cystic fibrosis. , 1974, Lancet.

[40]  Evans Jw.  SPECIAL" CALLS IN GENERAL PRACTICE. , 1963 .

[41]  E. Carlinfanti,et al.  Use of a tourniquet to prolong the effect of penicillin. , 1947, Lancet.